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Abstract  63 
Background  64 
Diabetes is associated with increased fracture risk but we do not know what affects this 65 
risk. We investigated the risk of hip and non-vertebral fractures in diabetes and whether 66 
 4 
this risk was affected by age, gender, body mass index, diabetes type and duration, 67 
insulin use and diabetic complications.  68 
 69 
Methods 70 
We selected a previously published review to be updated.  MEDLINE, Embase and 71 
Cochrane databases were searched up to March 2020. We included observational 72 
studies with age and gender-adjusted risk of fractures in adults with diabetes compared 73 
to adults without diabetes. We extracted data from published reports that we 74 
summarised using random effects model. 75 
 76 
Findings  77 
From the 3140 records identified, 49 were included, 42 in the hip fracture analysis, 78 
reporting data from 17,571,738 participants with 319,652 fractures and 17 in the non-79 
vertebral fracture review, reporting data from 2,978,487 participants with 181,228 80 
fractures. We found an increase in the risk of fracture in diabetes both for hip (RR 4.93, 81 
3.06-7.95, in type 1 diabetes and RR1.33, 1.19-1.49, in type 2 diabetes) and for non-82 
vertebral fractures (RR 1.92, 0.92-3.99, in type 1 and RR 1.19, 1,11-1.28 in type 2).  At the 83 
hip, the risk was higher in the younger population in both type 1 and type 2 diabetes. 84 
In those with type 2 diabetes, longer diabetes duration and insulin use was associated 85 
with an increased risk. We did not investigate the effect of bone density, falls, anti-86 
diabetic drugs and hypoglycemia. 87 
 88 
Conclusion   89 
 5 
Diabetes is associated with an increase in both hip and non-vertebral fracture risk. 90 
 91 
Highlights 92 
The risk of hip fractures was greater in T1D than T2D 93 
Hip fracture risk is higher in in people younger than 65 years for both type 1 and type 94 
2 diabetes 95 
In type 2 diabetes, insulin use and longer diabetes duration is associated with greater 96 











Introduction  108 
Diabetes is a public health concern. The global prevalence has recently increased from 109 
4.7% to 8.5%. In 2016, 1.6 million deaths were directly caused by diabetes (1). Fractures 110 
are also a public health concern. Notably, up to 20% of patients die in the first year 111 
after a hip fracture, and less than half regain the previous level of function (2). People 112 
 6 
with diabetes have higher mortality after a hip fracture as compared to people without 113 
diabetes (3).  114 
Fractures at the spine, hip, wrist and humerus are considered major osteoporotic 115 
fractures. Whilst hip, wrist and humerus fractures are usually captured by hospital 116 
records, vertebral fractures are often asymptomatic. They are largely underdiagnosed 117 
and their identification requires spinal imaging. A recent review on the risk of vertebral 118 
fractures was based on individual participant data from cohorts, since registry data 119 
would not be reliable (4). Hip fractures are associated with the greatest morbidity and 120 
mortality. The analysis of non-vertebral fractures allows a comprehensive approach not 121 
affected by the complexity of assessing vertebral fractures, enabling the use of registry 122 
data. A number of reviews have assessed the risk of fractures in diabetes but they have 123 
not explored the risk of non-vertebral fractures as a group nor the effect of important 124 
features such as age, body mass index (BMI), diabetes duration, insulin use and the 125 
presence of complications (4-10). The aim of this systematic review and meta-analysis 126 
was to update the risk of hip fracture and to assess the risk of non-vertebral fractures 127 
in adults with diabetes compared to adults without diabetes in observational studies. 128 
We also assessed if gender, age, BMI and diabetes-related features such as diabetes 129 
type, duration, insulin use and the presence of complications affect this risk.  130 
 131 
Methods  132 
Search strategy and selection criteria  133 
This review complies with key principles from the Cochrane Handbook and the Centre 134 
for Reviews Dissemination Handbook (11, 12). This report followed the Preferred 135 
 7 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and MOOSE 136 
guidelines (13, 14). The protocol was registered in PROSPERO (CRD42018090378).  137 
The search strategy was to identify a published systematic review that we could then 138 
update. Searches were conducted on 9th March 2018 (MEDLINE, Embase and Cochrane 139 
databases) and updated (primary study) up to 25th March 2020 (MEDLINE). The full 140 
search strategies are described in appendix 1. In summary, we combined terms for 141 
fractures and diabetes mellitus and related synonyms including free and thesaurus 142 
terms. The most comprehensive review with inclusion and exclusion criteria similar to 143 
this review was selected. The primary study research was conducted from the date of 144 
the selected review search, June 2006. The reference lists of key existing reviews were 145 
searched for additional primary studies (5, 7-9, 15) and experts in the field were 146 
consulted for additional relevant studies. 147 
 We included systematic reviews of observational studies (review of systematic reviews) 148 
or summary estimates of observational studies that reported age and gender adjusted 149 
risk of hip and/or non-vertebral fractures in adults (>18 years) with diabetes compared 150 
to participants without diabetes. Studies were excluded if: the diabetes 151 
definition/diagnosis or the comparator group was unclear; the diabetes diagnosis was 152 
made after the fracture or where the sequence was unclear; only data including 153 
spine/vertebral fractures were reported; fracture risk was based on an algorithm or risk 154 
tool; outcome data was unclear, missing or incomplete; the study was not in English; or 155 
was a narrative review, letter, editorial, commentary, conference abstract, animal or 156 
biological study.  157 
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 For both the previous reviews and primary studies searches, one reviewer excluded 158 
clearly irrelevant records on the basis of their title and abstracts. A second reviewer 159 
independently sifted a 10% sample and the kappa statistic for the agreement was 160 
calculated. The full text sift was conducted by one reviewer in the reviews search and 161 
independently by two reviewers in the primary study search. Disagreements at any step 162 
were resolved through discussion or involvement of a third reviewer. 163 
 164 
Data analysis 165 
Search results were uploaded to Endnote and the duplicates were removed. Two 166 
reviewers independently conducted the data extraction, the quality assessment and the 167 
data checking using standardized and piloted forms (appendix 2 and 3). The full text of 168 
studies included in the existing systematic review were revisited for data extraction and 169 
quality assessment. For each study, we extracted the author, date, country, diabetes 170 
type, age, follow-up, population (total/ DM), number of fractures, ethnicity, gender, 171 
fracture site and risk estimate.  172 
We used the Newcastle Ottawa Scales (NOS) to assess study quality (appendix 3). The 173 
tool assesses the selection and comparability of the study groups, and the 174 
ascertainment of exposure (for case-control studies) or outcome of interest (for 175 
cohort studies). Stars are awarded to a maximum of nine. We considered studies 176 
scoring equal or greater than seven to be high quality. We conducted a narrative 177 
synthesis, including tabulation of study characteristics, and a description of the 178 
available data.  179 
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Some studies reported the risk estimates in several categories, such as gender, age 180 
groups and diabetes type. Studies that reported more than two risk estimate for a 181 
given group in the subgroup analyses were summarised using the random-effects 182 
model, before the main analysis. For the non-vertebral fracture analyses, studies that 183 
reported the risk of fractures for two or more sites were summarised using the 184 
random effects model.   185 
Subgroup analyses anticipated in the protocol (gender, age, BMI, DM type and 186 
duration, insulin use and the presence of complications) and an exploratory analysis for 187 
the same features for each diabetes type were performed when enough data was 188 
available. The ratio of relative risk (RRR) and the 95% CI was applied to compare the 189 
risk (16). Studies that described the same population but reported the risk for different 190 
subgroups were included in different subgroup analysis, but a given population/cohort 191 
was not included twice in the same analysis. For the overall analysis the most 192 
comprehensive data was included. We used the random-effects model (DerSimonian 193 
& Laird method) to pool the studies.  194 
Heterogeneity, when high, was explored by subgroup analysis, sensitivity analysis and 195 
meta-regression. Subgroup analyses were performed when enough data was available. 196 
We performed a sensitivity analysis excluding one study at a time, the case-control 197 
studies, the studies that scored less than seven in the quality assessment and each kind 198 
of risk estimate included (e.g. hazard ratio). In the hip fracture analysis, meta-regression 199 
was performed to assess how much of the variation observed was due to diabetes type 200 
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or age group (< 65 years vs > 65 years). We used STATA/IC 16.0 software (StataCorp, 201 
USA).  202 
 203 
Results  204 
The search for systematic reviews identified 452 unique records, 388 excluded on the 205 
assessment of the title and abstract. From the remaining 64 records, eight reviews 206 
reported the risk of fractures in diabetes and one was selected (6). The kappa statistic 207 
for the agreement between reviewers about studies selection was perfect (1.00 95%CI 208 
1.0, 1.0).   209 
The search process of primary studies is described in the PRISMA diagram (fig 1). From 210 
the 3140 records identified, 221 underwent full-text assessment and 49 studies met the 211 
inclusion criteria. Of these, 48 were included in the meta-analyses, 42 in the hip 212 
fractures analysis (17-58) and 17 in the analysis of non-vertebral fractures (17, 21, 28, 30, 213 
32, 34, 36, 50, 52, 53, 56, 57, 59-63). Studies that included some or all of the same 214 
patients as another study (overlapping studies) were included if they reported different 215 
aspects of that population that could be used in our subgroup analyses. Potential small 216 







Records identified through 
database searching 
(n = 3000) 
 
Update (n=140) 
Additional records identified 
through other sources 
(n = 32) 
Records after duplicates removed 





















Fig 1 Prisma Flowchart (List of papers excluded at full text in appendix 4) 238 
 239 
Hip fractures  240 
 241 
Hip fracture study characteristics  242 
Table 1 summarises the study characteristics. Forty-three studies reported data on hip 243 
fracture risk in people with diabetes compared to people without diabetes (17-58, 64). 244 
Six analysed overlapping populations but reported subgroup data relevant to our 245 
subgroup analyses (19-21, 28, 29, 38-40, 44, 45, 64). One study with overlapping 246 
Full-text articles excluded, with 
reasons 
(n =172) 
No data on fracture risk in diabetes 
(n=47) 
Includes vertebral fractures (n=39) 
Sequence of fracture and diabetes (14) 
No adequate control group (n=21) 
Data not adjusted for age and sex 
(n=15) 
Publication or study type (n=11) 
All or some children (n=8) 
Some or all patients included in 
another included study (n=6) 
Diabetes diagnosis unclear or 
inadequate (n=4) 
Missing data (n=3) 
Not in English language (n=3) 
Algorithm to predict risk (n=1) 
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population was the only study to report the RR according to metabolic control and was 247 
not included in the meta-analysis (64). Forty studies were cohorts  (17-23, 25-48, 50-248 
53, 55-58, 64) and three studies were case-control studies (24, 49, 54). The study size 249 
varied from 238 (54) to 3,861,874 participants (31). Nineteen studies were from North 250 
America; five from Canada (38-42) and others from the USA (18, 24, 33, 36, 37, 43, 47-251 
49, 51-53, 55, 56). Sixteen studies were  from Europe; three from Norway (17, 23, 46), 252 
two from the Netherlands (21, 64), one from Austria (22), three from the United 253 
Kingdom (27, 31, 58), two from Denmark (28, 29), two from Sweden (30, 57), two from 254 
Spain (44, 45), and one from Germany (50). Five studies were from Asia (Taiwan (19, 255 
20), Korea (34), Singapore (35) and Israel (54) and three from Australia (25, 26, 32). Two 256 
studies reported data only from T1D participants (26, 58),  ten studies reported data 257 
only from T2D participants (21, 22, 25, 34, 44, 45, 49, 50, 53, 64) and the others reported 258 
data from participants of both DM types (17, 23, 27, 31, 33, 37-39, 41-43, 47, 57) or did 259 
not specify the participant’s DM type (18-20, 24, 28-30, 32, 35, 36, 40, 46, 48, 51, 52, 260 
54-56).  Ages varied from 20 to 100 years. Six studies reported data just from women 261 
(22, 33, 36, 40, 47, 53) and three just from men (37, 45, 49). The other studies reported 262 
data from both.  Not all studies reported the population ethnicity.   Studies from Asia 263 
were included (19, 20, 34, 35, 54) and some studies from North America included blacks 264 
and Hispanics (18, 36, 37, 43, 48, 51, 52, 55, 56) , but the majority of data reported 265 
addressed white populations. The studies reported relative risk, odds ratio, hazard ratio 266 
and incidence rate ratio. For simplicity they will be called relative risk. Overall the quality 267 
of the studies was good as most scored higher than seven, which is considered high 268 
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quality. The full description of the criteria and the author’s judgement with reason is 269 
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Fol up Follow-up;; F female; M male; NHS Nurses’ Health Study; KNHIS Korean National Health Insurance Service; EPESE North Carolina Established Populations 
for Epidemiologic Studies of the Elderly; NHW non-Hispanic white; NHB non-Hispanic black; MA Mexican American; ARIC The Atherosclerosis Risk in Communities 
Study;  SOF Study of Osteoporotic Fractures; CHS Cardiovascular Health Study; FRAILCO Fractures and Fall Injuries in the Elderly Cohort; THIN The Health 
Improvement Network; WHI-OS Women’s Health Initiative- Observational Cohort; NHW - NHIS Non-Hispanic white; F female; NHIS- NSC National Health 
Insurance Service National Sample Cohort of the Korean National Health Insurance Service; Md median; p-y person-years;;   
 
 
1Prospective Cohort; 2Retrospective Cohort; 3Case-control  
Adjustments: 
3 Age adjusted, reported by sex 
4 Age and sex 
5 Age as a continuous variable, geographic area, and urbanization status 
6 Groups were matched for sex, age and the year of diagnosis of DM 
7 Age, gender, BMI, smoking, serum creatinine, visual acuity, falling frequency, lower limb disability 
8 Age, sex, height, weight 
9 Age and weight 
10 Age, BMI and daily smoking 
11 Age and sex matched controls 
12 Ethnic origin, alcohol intake, smoking, age, BMI, medical or social factors (Asthma or chronic obstructive airways disease, any cancer, cardiovascular disease, 
dementia, epilepsy diagnosis or prescribed anticonvulsants , history of falls, chronic liver disease, Parkinson’s disease, rheumatoid arthritis or systemic lupus 
 26
erythematosus Chronic renal disease, Type 1 diabetes, Type 2 diabetes, previous fracture, endocrine disorders, gastrointestinal malabsorption, parental history of 
osteoporosis, any antidepressants, corticosteroids, unopposed hormone replacement therapy 
13 Adjusted for baseline age, BMI group (<20, 20–30, >30), modified Charlson index, estrogen deficiency, MOF, prevalent rheumatoid arthritis, former osteoporosis 
treatment, glucocorticoid use >450 prednisone eq., family fracture history, current smoking, exercise level, prevalent alcohol related diagnoses 
14 Age, gender, income, calendar year and comorbidity (ischemic heart disease, COPD, dementia, depression, diabetes, osteoporosis and stroke) 
15 Age, calendar year, SIMD, and for the overall estimate, an SIMD‐age interaction 
16 Age 
17 Age at recruitment, sex (for all), year of recruitment, dialect group (Hokkien, Cantonese), level of education (no formal education, primary, secondary or higher) 
18 Age, race, BMI 
19 Adjusted for age, race/ethnicity, tobacco use, alcohol use, glucocorticoid use, rheumatoid arthritis, and BMI. 
20 Age, sex, income quintile, are of residence and ethnicity 
21 Age, sex, BMI, glucocorticoid use, rheumatoid arthritis, high alcohol use, any prior fracture, and femoral neck T-score 
22 Frax adjusted 
23 Adjusted for age, sex, and BMD femoral neck T-scores 
24 Age group chronic unstable disease; prior stroke; visual impairment; neuropathy; amputation; treatment with nitrates, statins, anticonvulsants, inhaled 
corticosteroids, thiazides, estrogen, and medications that increase risk of falling; and history of BMD test 
25 Age, sex and survey 
26 Age and sex matched  
27 Age, body mass index, smoking, alcohol consumption, use of oral corticosteroids, and co-morbid conditions (COPD Heart failure Chronic kidney disease, severe 
liver disease MLDa malignant tumour (without metastasis), metastasis, connective tissue disease, AIDS, paraplegia, dementia, peptic ulcer disease, myocardial 
infarction, cerebrovascular disease, peripheral vascular disease 
28 Age, gender, smoking status, BMI, and history of stroke. 
29 Age, sex, diabetologist care, depression, chronic kidney disease, peripheral vascular disease, heart failure, hyperlipidemia, obesity. 
30Age, self-reported health, height, change in height since the age of 18 years, change in weight since the age of 35 years, history of fracture after the age of 55 
years, race/ethnicity, physical activity, smoking, history of parental fracture after the age of 40 years, diabetes treated with medications, and corticosteroid use 
31 Age, sex and race/study center, body mass index, sports-activity tertile, alcohol consumption, cigarette smoking, and medication use. 
 27
32 Plasma PTH serum 25(OH)D3 concentration, concomitant diseases (hypertension, ischemic heart disease and diabetes mellitus), smoking status, age, gender 
and season. 
33 Age-sex-race adjusted 
34 Gender, race-ethnicity, age, calendar year, urban/rural, geographic location, median income, previous fracture, other predisposing conditions (glucocorticoid 
related, fall-related, renal disease, depressive illness, AMI, other heart disease, bone disease, cancer) 
35 Matched by age, sex, and GP practice. 
36 Five-year age, gender, and race/ethnicity, as indicated by inpatient medical files (White, non-White, and unknown), and the following: age in years, self-reported 
race/ethnicity, and type of interview (in person vs. over the telephone). 
37 Adjusted for age, race, clinic 
38 Age, race, sex, clinic site, and total hip BMD
Hip fractures – meta-analysis results 301 
The summary of the 37 (out of 42) non-overlapping studies resulted in a RR of 1.58, 302 
95%CI 1.48-1.70 and high heterogeneity (I2 96.9% p<0.001) (Fig 2). We explored the 303 
heterogeneity using subgroup and sensitivity analyses and meta-regression.  304 
 305 
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* Summarised using random-effects model DM diabetes mellitus 306 
Fig 2 Forest plot overall hip fracture risk in diabetes 307 
 308 
We performed subgroup analysis by gender, age (younger and older than 65 years 309 
old), diabetes type, insulin use, diabetes duration (using a 5- and 10-years cut-off) and 310 
BMI. When enough data was available the same analysis was performed in each 311 
diabetes type subgroup. Table 2 reports the results. The risk of hip fractures was higher 312 
in T1D compared to T2D and in the younger population compared to the elderly in 313 
both T1D and T2D. In T2D, the risk of hip fractures was higher in females than in males, 314 
in those using insulin compared to non-insulin users and in those with longer disease 315 
duration (>10 years). Finally, the analysis by BMI including both T1D and T2D did not 316 
detect difference between the groups.  There was not enough data to perform this 317 










Table 2 Subgroup analyses hip and non-vertebral risk of fracture in diabetes combined analysis (T1D and T2D) and by diabetes type 
Feature Subset  RR (95% CI)  n Het  RR (95% CI)  n Het  RR (95% CI)  n Het  
  
Overall DM analysis (T1D + T2D)  T1D  T2D  








4.93 (3.06,7.95)* 9 94.9% 
p<0.001 
1.37 (1.22, 2.21) 19 87.8% 
p<0.001 
Gender  Female  1.77 (1.54, 2.04)* 25 94.8% 
p<0.001  
4.54 (2.59, 7.94) 8 91.6% 
p<0.001  
1.34 (1.17, 1.54)* 12 91.0% 
p<0.001  
Male  1.35 (1.22, 1.49) 
  
3.66 (2.16, 6.18) 
  
1.13 (0.99, 1.29) 
  
Age (65 y 
cut-off) 
< 65 years 
old 
3.21 (2.38, 4.32)* 22 94.9% 
p<0.001 
5.21 (3.75, 7.22)* 3 86.1% 
p<0.001 
1.74 (1.24, 2.43)* 6 85.9% 
p<0.001  
> 65 years 
old 
1.21 (1.14, 1.28) 
  
2.48 (2.13, 2.89) 
  
























1.34 (1.09, 1.65) 5 60.8%  
p=0.003  












1.34 (1.09, 1.65)* 5 69.0%  
p=0.004  
























BMI > 30 
kg/m2 











1.24 (1.15, 1.32)* 17 53.4%, 
p=0.02 
1.92 (0.92, 3.99)  2 78.1% 
p=0.033 
1.19 (1.11, 1.28)  8 25.2% 
p=0.212  
Gender Female  1.19 (1.13-1.26) 11 0.0%, 
p=0.75 
1.65 (0.82, 3.29)  2 60.0% 
p=0.05 
1.17 (1.08, 1.27)  7 21.1% 
p=0.236   
Male 1.14 (1.03, 1.27) 
  
1.89 (1.04, 3.42) 
  
















1.04 (0.93, 1.16) 
  
DM dur  Prevalent  2.14 (1.72, 2.65)* 4 81.3%, 
p<0.001 
‡   ‡ 
  
 






n number of studies included; het heterogeneity; DM dur diabetes mellitus duration 




Few studies addressed the effect of diabetes control (n=1) or microvascular 334 
complications (n=1) on the risk of fractures, therefore, it was not possible to perform 335 
subgroup analyses. Oie et al reported that, in patients with inadequate control, there 336 
was an increase in the risk of all fractures and wrist fractures, but not for hip fractures 337 
(64). Lee et al reported that neuropathy explained around 20% of the risk of hip and 338 
any fractures (37). These meta-analyses report the data of 17,571,738 participants, 339 
2,387,479 with DM and 319,652 fractures. 340 
We ran the analyses excluding one study at a time and no important variation was 341 
observed in the RR or heterogeneity. We also excluded the case-control studies, and 342 
each kind of risk estimate (e.g. OR, HR) and found similar results in the RR and 343 
heterogeneity. Meta-regression analysis showed that age (65 years old cut-off) and DM 344 
type accounted for 83% of the RR of hip fractures in diabetes. 345 
 346 
Non-vertebral fractures  347 
Table 1 summarises the study characteristics. Eighteen studies reported the risk of 348 
fractures in two or more sites and 17 were included in the non-vertebral fractures risk 349 
analysis (17, 21, 28, 30, 32, 34, 36, 50, 52, 53, 56, 57, 59-64). One overlapping study was 350 
the unique to report the risk of fractures (wrist and hip) for metabolic control and could 351 
not be included in the meta-analysis calculations.  All but one study (61) were cohorts,  352 
(17, 21, 28, 30, 32, 34, 36, 50, 52, 53, 56, 57, 59, 60, 62-64). Eight studies were from the 353 
USA (36, 52, 53, 56, 59, 61-63), seven from Europe (one from Norway (17); two from the 354 
Netherlands (21, 64); one from Denmark (28); two from Sweden (30, 57) and one from 355 
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Germany (50)); the two Asian studies were from Korea (34, 60) and one study from 356 
Australia (32). Nine studies did not specify diabetes type (30, 32, 36, 52, 56, 60-63),  357 
while seven reported data just from T2D (21, 28, 34, 50, 53, 59, 64) and two from both 358 
types (17, 57). Five studies reported data just from women (28, 36, 53, 59, 60), one just 359 
from men (62) and the others from both genders (17, 21, 30, 32, 34, 50, 52, 56, 57, 61, 360 
63, 64). The age range varied from 20 to 98 years. The study size varied from 1,949 (63) 361 
to 1,694,051 participants (56). Although other ethnicities were included, such as Asian, 362 
blacks, Hispanics and others (34, 36, 52, 59, 60, 62, 63, 65), the majority of the data 363 
addressed white populations. Nine studies reported the risk of non-vertebral fractures 364 
as a category (17, 21, 32, 34, 53, 57, 60, 62, 63) and the others reported several 365 
combinations of sites including axial and peripheral sites. Only one study did not 366 
include hip fracture (61). Overall the quality of the studies was good as most scored 367 
higher than seven, which is considered high quality (full description in appendix 5). 368 
 369 
Non-vertebral fractures meta-analysis results  370 
The risk of non-vertebral fractures was increased in diabetes (RR1.24 95%CI 1.15-1.32) 371 
and heterogeneity was moderate (I2 53.4%, p=0.02) (Fig 3). The risk in T1D was 1.92 95% 372 
CI 0.92-3.99 while in T2D was 1.19 95%CI 1.11-1.28. 373 
Subgroup analyses are reported in Table 2. The risk was not significantly different 374 
between T1D and T2D, but only two studies reported the risk on T1D. No difference was 375 
found between female and male (both for T1D and T2D) or between insulin users and 376 
non-insulin users in T2D. Due to a lack of enough data, age and BMI subgroup analyses 377 
were not performed. Sensitivity analyses did not affect the results. Seventeen studies 378 
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were included in this analysis, reporting data from 2,978,487 participants, 413,775 with 379 
diabetes and 181,228 fractures.  380 
 381 
* Summarised using random-effects model 382 
DM diabetes mellitus; NHNV non-hip non-vertebral fracture 383 
Fig 3 Forest plot non-vertebral fractures risk in diabetes 384 
 385 
 386 
Discussion  387 
There was an increase in the risk of hip and non-vertebral fractures in diabetes 388 
compared to those without diabetes. At the hip, the risk was higher in T1D than T2D. In 389 
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both T1D and T2D, the risk of hip fractures was higher in the younger population.  In 390 
T2D, the risk of hip fractures was higher in  females, insulin users and those with longer 391 
disease duration. 392 
The mechanism for the increase in the risk of fractures in diabetes is not understood 393 
and might be associated with several features. Some of them are common to both 394 
diabetes types. Diabetes is associated with an increased risk of falls (57, 66, 67), 395 
especially in those using insulin, those with microvascular complications and those with 396 
hypoglycaemic episodes (68-70). Chronic hyperglycaemia favours non-enzymatic 397 
reactions between proteins and glucose producing advanced glycation end products 398 
(AGEs) what might affect bone material properties (71).  399 
Conversely, bone mineral density (BMD) is discordant in T1D and T2D. In T1D, BMD is 400 
decreased, but the small decrease in BMD does not explain the huge increase in the 401 
risk of fractures (5). In T2D, BMD is increased and the risk of fractures is paradoxically 402 
increased as well, suggesting that bone fragility in diabetes is not explained by 403 
decreased BMD. Microarchitecture studies have reported favourable, neutral and 404 
unfavourable patterns in T2D (72-74). In T1D, unfavourable microarchitecture was 405 
reported in patients with microvascular disease (75). Therefore, the bone structure 406 
seems not to fully explain the bone fragility in diabetes (76).   407 
In T2D , antidiabetic drugs might also be involved. Increased risk of fractures has been 408 
associated with sulfonylureas, thiazolidenediones (TZD), glucagon like peptide 1 (GLP1 409 
analogues) and sodium/glucose co-transporter2 inhibitors (SGLT2 inhibitors) (77). Data 410 
from cohorts on metformin showed a neutral or positive effect on the risk of fractures 411 
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(77-79). Sulfonylureas have no direct effect on bone but they were associated with an 412 
increase in the risk of fractures, possibly due to hypoglycaemic episodes and falls (80). 413 
Conversely, data on incretin mimetics are inconsistent, with both decrease and increase 414 
in the risk described with GLP-1 (81) and a decreased risk associated with DPP-4 415 
inhibitors (82). TZD increase adipogenesis and impair osteoblastogenesis and were 416 
associated with an increase in the risk of fractures (80, 83). More recently, SGLT2 417 
inhibitor canaglifozin, but not empaglifozin or dapaglifozin, was also associated with 418 
an increase in the risk of fractures (80, 84). Therefore, several factors could affect the 419 
risk of fractures in diabetes.  420 
Several meta-analyses have reported an increase of hip fractures  (5, 8, 9, 85-87) both 421 
in T1D and T2D and any fractures in T1D (8, 88) but none of them has investigated the 422 
risk of non-vertebral fractures nor the effect of several features in the risk of fractures 423 
in this population. The results of this meta-analysis are consistent with previous studies 424 
as we reported an overall 58% increase in the risk of hip fractures, with a significant 425 
33% increase in the risk in T2D (26-70% previously reported) and a substantial 4 -fold 426 
increase in T1D (3-7 fold previously reported)(5, 6, 8, 9, 85, 89). This greater increase in 427 
T1D is probably associated with the lower BMD observed in T1D and the higher risk of 428 
hypoglycaemia and falls associated with insulin use (90). We speculate that the early 429 
onset of the disease, often before the peak of bone mass accrual might play a role (91).  430 
We are the first to report a greater increase in the risk of hip fractures in women (34%) 431 
than in men (13%) in T2D. We speculate that an interaction between female gender and 432 
diabetes might result in a greater increase in the risk in women. 433 
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This is the first meta-analysis to assess the effect of age, insulin use, diabetes duration 434 
and BMI on the risk of fractures in diabetes. In the hip fractures analysis, we found a 435 
greater increase in the RR of fractures in people with diabetes younger than 65 years 436 
old, than in the population older than 65 years old, for both T1D and T2D. The incidence 437 
of hip fractures in the younger than 65 years old is low (92) and the impact of an 438 
increase in the incidence of fractures associated with diabetes in the relative risk will be 439 
greater at this age range (93). As the population gets older and the background risk of 440 
fractures increases, the additional risk associated with diabetes play a less important 441 
role. In addition, diabetes is associated with premature mortality, which also impact the 442 
fracture risk (94).  443 
The subgroup analysis by BMI included few studies reporting mainly data from T2D and 444 
showed no difference between the groups. Obesity is associated with a lower risk of 445 
hip fractures, due to mechanical and endocrine mechanisms (95, 96). In the USA, 446 
estimates suggested that 85% of people with T2D are overweight or obese (97). Despite 447 
the high prevalence of obesity in T2D, overall the risk of fractures is still increased in 448 
this population and the mechanisms are unknown.   449 
In T2D, insulin use was associated with higher fracture risk. Since insulin is used in 450 
advanced T2D, this increased risk probably does not reflect an effect of insulin at the 451 
skeleton but its indication and adverse effects, such as hypoglycaemia and falls. Patients 452 
with longer diabetes duration also showed a greater increase in the risk for both hip 453 
(overall analysis and T2D) and non-vertebral fractures (overall analysis). These patients 454 
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are more likely to have diabetes complications and to be exposed to potentially harmful 455 
antidiabetic treatments.   456 
In the hip fractures analysis, we found high heterogeneity. Heterogeneity reflects the 457 
differences between studies (98). We included data from men and women, from 18 to 458 
100 years old, with both diabetes types so high clinical diversity is expected. In addition, 459 
data came from prospective and retrospective cohorts and case-control studies, from 460 
recruited participants and registry data, adding substantial methodological diversity. 461 
These features should be considered while interpreting the results. Although we found 462 
a 58% increase in the risk of hip fracture in diabetes, this is an overall estimate. The risk 463 
will vary according to gender, age, diabetes type, diabetes duration and treatment.  464 
This study has several strengths. This is the most comprehensive review on the risk of 465 
hip fractures, with the greater number of studies included in the meta-analysis (n=42 466 
compared with a maximum n=28 studies in previous reviews) (10) and most 467 
comprehensive subgroup analysis pooled so far. This is the first systematic review and 468 
meta-analysis on the risk of non-vertebral fractures in diabetes. The high heterogeneity 469 
found in the hip fracture analysis was extensively explored by subgroup and sensitivity 470 
analysis and meta-regression.  471 
However, this study also has limitations. This is a systematic review update, so we relied 472 
on the search done by the previous systematic review (6). However, reference lists of 473 
several previous reviews also were included as a source of papers. In addition, we used 474 
the original full text of these studies for data extraction and quality assessment. The 475 
initial study sifting was done by one reviewer but the random 10% double sifting kapa 476 
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statistic for agreement was good. Many studies do not report the risk by diabetes type 477 
(non-specified diabetes). However, the risk of fractures in these studies showed a 478 
pattern very similar to the T2D analysis (fig 2 and 3). In addition, T2D is estimated to 479 
account for 90% of the cases of diabetes (2). Therefore, it is likely that the majority of 480 
data from the non-specified diabetes study is related to T2D. We could not investigate 481 
the effect of BMD, falls, the competing risk of death, metabolic control, the presence of 482 
microvascular complications, the effect of anti-diabetic drugs and hypoglycemia on the 483 
risk of fractures. 484 
The criteria to establish osteoporosis diagnosis in diabetes is based on the presence of 485 
fragility fractures and/or low BMD (as in general population). However, since BMD and 486 
fracture prediction tools, such as FRAX, underestimate this risk (99, 100), the IOF Bone 487 
and Diabetes Working group suggested that patients with diabetes should be 488 
considered for treatment at more favourable BMD and FRAX values than patients 489 
without diabetes (77).  490 
There is no specific treatment for bone fragility in diabetes. As for all complications 491 
associated with diabetes, adequate metabolic control is advisable. However, the risk of 492 
hypoglycaemia should be considered, especially in the elderly (90, 101, 102). In addition, 493 
antidiabetic medications with unfavourable effect on bone metabolism should be 494 
avoided in patients with diabetes and bone fragility (77). Most previous studies with 495 
anti-osteoporotic medications showed similar effects on BMD and fracture risk in 496 
people with and without diabetes (103, 104). However, most of the data available 497 
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assessed postmenopausal women with T2D and additional data about anti-fracture 498 
efficacy in other groups such as males, T1D and younger populations is required.  499 
In summary, this meta-analysis highlights the complexity of assessing the risk of 500 
fractures in diabetes. Evidence suggest a different mechanism from osteoporosis, since 501 
bone fragility in diabetes is not directly associated with reduced BMD. The increase in 502 
the risk of fractures is observed in both T1D and T2D, suggesting that features common 503 
to both types such as hyperglycemia and the development of microvascular 504 
complications might be involved. Conversely, the substantially higher risk observed in 505 
T1D suggest that mechanisms associated with the different pathophysiology (early 506 
onset, lack of endogenous insulin) might have an important impact in the risk in T1D. 507 
Despite growing evidence on the increased risk of fractures in diabetes, the skeleton is 508 
not widely recognised as a site for diabetic complications. In addition, there is limited 509 
data on the assessment of fracture risk, the impact of the increased risk of fractures in 510 
diabetes management and the efficacy and safety of anti-osteoporotic treatments in 511 
diabetes. The population with diabetes is heterogeneous and identifying groups with 512 
higher risk of fractures is a key factor. This could allow policies and practices to target 513 
specific groups. In addition, this is a first step to guide future research in order to 514 




Authors’ contribution: Study design: TV, EP, SC, RE. Data collection: TV, MS, SH, AS, 518 
EP. Data analysis and interpretations: TV, MS, SH, IA, SC, RE. Manuscript drafting: TV, 519 
RE. All authors have revised and approved the manuscript. 520 
 521 
Acknowledgements 522 
The project has been funded by Amgen Inc (USA), however, the funders had no role 523 
in the study design, data collection, analysis, reporting, or the decision to submit for 524 
publication. 525 
 526 
Declaration of interest  527 
TV received grant funding from Amgen Inc and personal fees from Conselho 528 
Nacional de Desenvolvimento Científico e Tecnológico - CNPq- Brazil. 529 
MS received grant funding from Amgen Inc and personal fees from the Centre For 530 
Integrated Research Into Musculoskeletal Ageing (CIMA) and Osteoporosis 2000. 531 
SH received grant funding from Amgen Inc. 532 
EP received grant funding from Amgen Inc. 533 
AS received grant funding from Amgen Inc. 534 
 42 
SC received consultancy and grant funding from Amgen Inc. 535 
IA received grant funding from Amgen Inc. 536 
RE received consultancy funding from Immunodiagnostic Systems, Roche Diagnostics, 537 
GSK Nutrition, FNIH, Mereo, Lilly, Sandoz, Nittobo, Abbvie, Samsung, Haoma Medica 538 
and grant funding from Nittobo, IDS, Roche Diagnostics, Amgen Inc and Alexion 539 
 43 
References  
1. World Health Organization -Diabetes 2019 [Available from: https://www.who.int/health-
topics/diabetes. 
2. International Osteoporosis Foundation - Facts and Statistics 2019 [Available from: 
https://www.iofbonehealth.org/facts-statistics. 
3. Tebe C, Martinez-Laguna D, Carbonell-Abella C, Reyes C, Moreno V, Diez-Perez A, et al. 
The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: 
a multi-state cohort analysis. Osteoporos Int. 2019. 
4. Koromani F, Oei L, Shevroja E, Trajanoska K, Schoufour J, Muka T, et al. Vertebral Fractures 
in Individuals With Type 2 Diabetes: More Than Skeletal Complications Alone. Diabetes Care. 
2020;43(1):137-44. 
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with 
type 1 and type 2 diabetes - a meta-analysis. Osteoporosis International. 2007;18(4):427-44. 
6. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 
diabetes mellitus and risk of fracture. American Journal of Epidemiology. 2007;166(5):495-505. 
7. Jia P, Bao L, Chen H, Yuan J, Liu W, Feng F, et al. Risk of low-energy fracture in type 2 
diabetes patients: a meta-analysis of observational studies. Osteoporos Int. 2017;28(11):3113-
21. 
8. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. 
Osteoporos Int. 2016;27(1):219-28. 
9. Dytfeld J, Michalak M. Type 2 diabetes and risk of low-energy fractures in postmenopausal 
women: meta-analysis of observational studies. Aging Clin Exp Res. 2016. 
10. Bai J, Gao Q, Wang C, Dai J. Diabetes mellitus and risk of low-energy fracture: a meta-
analysis. Aging Clin Exp Res. 2019. 
11. Higgins J, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 
2011;www.handbook.cochrane.org. 
12. Akers J, Aguiar-Ibáñez R, Baba-Akbari Sari AJYCfR, Dissemination. CRD’s guidance for 
undertaking reviews in health care. 2009. 
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. 
14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of 
observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational 
Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008-12. 
15. Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. 
Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic 
review and meta-analysis. Ther Clin Risk Manag. 2017;13:455-68. 
16. Hutchon DJ. 2005. 
17. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H. Diabetes mellitus and 
the risk of non-vertebral fractures: the Tromso study. Osteoporos Int. 2006;17(4):495-500. 
 44 
18. Berry SD, Zullo AR, Lee Y, Mor V, McConeghy KW, Banerjee G, et al. Fracture Risk 
Assessment in Long-term Care (FRAiL): Development and Validation of a Prediction Model. J 
Gerontol A Biol Sci Med Sci. 2018;73(6):763-9. 
19. Chen HF, Ho CA, Li CY. Increased risks of hip fracture in diabetic patients of Taiwan: a 
population-based study. Diabetes Care. 2008;31(1):75-80. 
20. Lai S-W, Lin C-L, Liao K-F. Increased Risk of Hip Fracture in Diabetic Elderly. Kuwait Medical 
Journal. 2015;47:115-7. 
21. de L, II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density 
and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 
2005;16(12):1713-20. 
22. Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, et al. 
Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and 
fracture risk. J Clin Endocrinol Metab. 2006;91(9):3355-63. 
23. Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip 
fracture: results from the Nord-Trondelag Health Survey. Diabetologia. 1999;42(8):920-5. 
24. Gerber Y, Melton LJ, 3rd, McNallan SM, Jiang R, Weston SA, Roger VL. Cardiovascular and 
noncardiovascular disease associations with hip fractures. Am J Med. 2013;126(2):169.e19-26. 
25. Hamilton E, Davis WA, Bruce DG, Davis TM. Influence of Premature Mortality on the Link 
Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study. J Clin Endocrinol 
Metab. 2017;102(2):551-9. 
26. Hamilton EJ, Davis WA, Bruce DG, Davis TME. Risk and associates of incident hip fracture 
in type 1 diabetes: The Fremantle Diabetes Study. Diabetes Res Clin Pract. 2017;134:153-60. 
27. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to 
predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open 
cohort study. Bmj. 2012;344:e3427. 
28. Holm JP, Jensen T, Hyldstrup L, Jensen JB. Fracture risk in women with type II diabetes. 
Results from a historical cohort with fracture follow-up. Endocrine. 2018;60(1):151-8. 
29. Jorgensen TS, Hansen AH, Sahlberg M, Gislason GH, Torp-Pedersen C, Andersson C, et al. 
Falls and comorbidity: the pathway to fractures. Scand J Public Health. 2014;42(3):287-94. 
30. Holmberg AH, Johnell O, Nilsson PM, Nilsson J, Berglund G, Akesson K. Risk factors for 
fragility fracture in middle age. A prospective population-based study of 33,000 men and women. 
Osteoporos Int. 2006;17(7):1065-77. 
31. Hothersall EJ, Livingstone SJ, Looker HC, Ahmed SF, Cleland S, Leese GP, et al. 
Contemporary risk of hip fracture in type 1 and type 2 diabetes: a national registry study from 
Scotland. J Bone Miner Res. 2014;29(5):1054-60. 
32. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue 
Mountains Eye Study. Diabetes Care. 2001;24(7):1198-203. 
33. Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of 
hip fracture: the Nurses' Health Study. Diabetes Care. 2006;29(7):1573-8. 
34. Kim SH, Kim YM, Yoo JS, Choe EY, Kim TH, Won YJ. Increased risk of hip fractures in Korean 
patients with type 2 diabetes: a 6-year nationwide population-based study. J Bone Miner Metab. 
2017;35(6):623-9. 
 45 
35. Koh WP, Wang R, Ang LW, Heng D, Yuan JM, Yu MC. Diabetes and risk of hip fracture in 
the Singapore Chinese Health Study. Diabetes Care. 2010;33(8):1766-70. 
36. Lee RH, Pieper CF, Colon-Emeric C. Functional Impairments Mediate Association Between 
Clinical Fracture Risk and Type 2 Diabetes Mellitus in Older Women. J Am Geriatr Soc. 
2015;63(8):1546-51. 
37. Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Van Houtven C, et al. Clinical Fractures 
Among Older Men With Diabetes Are Mediated by Diabetic Complications. J Clin Endocrinol 
Metab. 2018;103(1):281-7. 
38. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: 
a population-based study. Bone. 2007;40(6):1595-601. 
39. Leslie WD, Morin SN, Lix LM, Majumdar SR. Does diabetes modify the effect of FRAX risk 
factors for predicting major osteoporotic and hip fracture? Osteoporos Int. 2014;25(12):2817-24. 
40. Majumdar SR, Leslie WD, Lix LM, Morin SN, Johansson H, Oden A, et al. Longer Duration 
of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort. J Clin 
Endocrinol Metab. 2016;101(11):4489-96. 
41. Li G, Prior JC, Leslie WD, Thabane L, Papaioannou A, Josse RG, et al. Frailty and Risk of 
Fractures in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(4):507-13. 
42. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals 
with diabetes: a population-based study. Diabetes Care. 2007;30(4):835-41. 
43. Looker AC, Eberhardt MS, Saydah SH. Diabetes and fracture risk in older U.S. adults. Bone. 
2016;82:9-15. 
44. Martinez-Laguna D, Tebe C, Javaid MK, Nogues X, Arden NK, Cooper C, et al. Incident type 
2 diabetes and hip fracture risk: a population-based matched cohort study. Osteoporos Int. 
2015;26(2):827-33. 
45. Reyes C, Estrada P, Nogues X, Orozco P, Cooper C, Diez-Perez A, et al. The impact of 
common co-morbidities (as measured using the Charlson index) on hip fracture risk in elderly 
men: a population-based cohort study. Erratum appears in Osteoporos Int. 2014 Sep;25(9):2333 
Note: Macias, J G corrected to Gonzalez-Macias, J. Osteoporosis International. 2014;25(6):1751-
8. 
46. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian 
women and men. Am J Epidemiol. 1993;137(11):1203-11. 
47. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in 
postmenopausal women. Diabetes Care. 2001;24(7):1192-7. 
48. Ottenbacher KJ, Ostir GV, Peek MK, Goodwin JS, Markides KS. Diabetes mellitus as a risk 
factor for hip fracture in mexican american older adults. J Gerontol A Biol Sci Med Sci. 
2002;57(10):M648-53. 
49. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ, 3rd. Predictors of hip fractures in elderly 
men. J Bone Miner Res. 1995;10(12):1900-7. 
50. Rathmann W, Kostev K. Fracture risk in patients with newly diagnosed type 2 diabetes: a 
retrospective database analysis in primary care. J Diabetes Complications. 2015;29(6):766-70. 
51. Robbins J, Aragaki AK, Kooperberg C, Watts N, Wactawski-Wende J, Jackson RD, et al. 
Factors associated with 5-year risk of hip fracture in postmenopausal women. Jama. 
2007;298(20):2389-98. 
 46 
52. Schneider AL, Williams EK, Brancati FL, Blecker S, Coresh J, Selvin E. Diabetes and risk of 
fracture-related hospitalization: the Atherosclerosis Risk in Communities Study. Diabetes Care. 
2013;36(5):1153-8. 
53. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older 
women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol 
Metab. 2001;86(1):32-8. 
54. Segal E, Raichlin V, Rimbrot S, Zinman C, Raz B, Ish-Shalom S. Hip fractures in the elderly 
in Israel-possible impact of preventable conditions. Arch Gerontol Geriatr. 2009;48(2):182-5. 
55. Strotmeyer ES, Kamineni A, Cauley JA, Robbins JA, Fried LF, Siscovick DS, et al. Potential 
explanatory factors for higher incident hip fracture risk in older diabetic adults. Curr Gerontol 
Geriatr Res. 2011;2011:979270. 
56. Taylor AJ, Gary LC, Arora T, Becker DJ, Curtis JR, Kilgore ML, et al. Clinical and demographic 
factors associated with fractures among older Americans. Osteoporos Int. 2011;22(4):1263-74. 
57. Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 Diabetes and Risk 
of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall 
Injuries in the Elderly Cohort (FRAILCO). J Bone Miner Res. 2017;32(3):449-60. 
58. Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR. Type 1 diabetes is associated 
with an increased risk of fracture across the life span: a population-based cohort study using The 
Health Improvement Network (THIN). Diabetes Care. 2015;38(10):1913-20. 
59. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of 
fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J 
Clin Endocrinol Metab. 2006;91(9):3404-10. 
60. Jung JK, Kim HJ, Lee HK, Kim SS, Shin CS, Kim JT. Fracture incidence and risk of osteoporosis 
in female type 2 diabetic patients in Korea. Diabetes Metab J. 2012;36(2):144-50. 
61. Keegan TH, Kelsey JL, Sidney S, Quesenberry CP, Jr. Foot problems as risk factors of 
fractures. Am J Epidemiol. 2002;155(10):926-31. 
62. Napoli N, Strotmeyer ES, Ensrud KE, Sellmeyer DE, Bauer DC, Hoffman AR, et al. Fracture 
risk in diabetic elderly men: the MrOS study. Diabetologia. 2014;57(10):2057-65. 
63. Schafer AL, Vittinghoff E, Lang TF, Sellmeyer DE, Harris TB, Kanaya AM, et al. Fat 
infiltration of muscle, diabetes, and clinical fracture risk in older adults. J Clin Endocrinol Metab. 
2010;95(11):E368-72. 
64. Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castano-Betancourt MC, Estrada K, et al. 
High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of 
inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013;36(6):1619-28. 
65. Petit MA, Paudel ML, Taylor BC, Hughes JM, Strotmeyer ES, Schwartz AV, et al. Bone mass 
and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study. J Bone 
Miner Res. 2010;25(2):285-91. 
66. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, et al. Older women 
with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25(10):1749-
54. 
67. Maurer MS, Burcham J, Cheng H. Diabetes mellitus is associated with an increased risk of 
falls in elderly residents of a long-term care facility. J Gerontol A Biol Sci Med Sci. 
2005;60(9):1157-62. 
 47 
68. Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, et 
al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 
2008;31(3):391-6. 
69. Kachroo S, Kawabata H, Colilla S, Shi L, Zhao Y, Mukherjee J, et al. Association between 
hypoglycemia and fall-related events in type 2 diabetes mellitus: analysis of a U.S. commercial 
database. J Manag Care Spec Pharm. 2015;21(3):243-53. 
70. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, et al. 
Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and 
black adults: the health, aging, and body composition study. Arch Intern Med. 
2005;165(14):1612-7. 
71. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced 
cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos 
Int. 2006;17(10):1514-23. 
72. Shanbhogue VV, Hansen S, Frost M, Jorgensen NR, Hermann AP, Henriksen JE, et al. 
Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular 
disease. Eur J Endocrinol. 2016;174(2):115-24. 
73. Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, et al. High-
resolution peripheral quantitative computed tomographic imaging of cortical and trabecular 
bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 
2010;95(11):5045-55. 
74. Nilsson AG, Sundh D, Johansson L, Nilsson M, Mellstrom D, Rudang R, et al. Type 2 
Diabetes Mellitus Is Associated With Better Bone Microarchitecture But Lower Bone Material 
Strength and Poorer Physical Function in Elderly Women: A Population-Based Study. J Bone Miner 
Res. 2017;32(5):1062-71. 
75. Shanbhogue VV, Hansen S, Frost M, Jorgensen NR, Hermann AP, Henriksen JE, et al. Bone 
Geometry, Volumetric Density, Microarchitecture, and Estimated Bone Strength Assessed by HR-
pQCT in Adult Patients With Type 1 Diabetes Mellitus. J Bone Miner Res. 2015. 
76. Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against 
fractures in patients with diabetes? Calcif Tissue Int. 2011;88(3):209-14. 
77. Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, et al. Diagnosis and 
management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 
2018;29(12):2585-96. 
78. Wang P, Ma T, Guo D, Hu K, Shu Y, Xu HHK, et al. Metformin induces osteoblastic 
differentiation of human induced pluripotent stem cell-derived mesenchymal stem cells. J Tissue 
Eng Regen Med. 2018;12(2):437-46. 
79. Lee RH, Sloane R, Pieper C, Lyles KW, Adler RA, Van Houtven C, et al. Glycemic control and 
insulin treatment alter fracture risk in older men with type 2 diabetes mellitus. J Bone Miner Res. 
2019. 
80. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms 
of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208-19. 
81. Su B, Sheng H, Zhang MN, Bu L, Yang P, Li L, et al. Risk of bone fractures associated with 
glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled 
trials. Endocrine. 2015;48(1):107-15. 
 48 
82. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl Peptidase-4 Inhibitors and 
Bone Fractures A meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474-6. 
83. Palermo A, D'Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N. Oral anti-diabetic drugs 
and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int. 
2015;26(8):2073-89. 
84. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, et al. Effects of Canagliflozin 
on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 
2016;101(1):157-66. 
85. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 
diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505. 
86. Shah C, Shah R, Kinra G, Singuru S, Naidu M, Dang A. Risk of Fracture in Type 2 Diabetes 
Mellitus Patients: Meta-Analysis of Observational Studies. Value Health. 2015;18(7):A601. 
87. Wang J, You WJ, Jing ZH, Wang RB, Fu ZJ, Wang YG. Increased risk of vertebral fracture in 
patients with diabetes: a meta-analysis of cohort studies. International Orthopaedics. 
2016;40(6):1299-307. 
88. Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis 
and review of the literature. Diabet Med. 2015;32(9):1134-42. 
89. Wang H, Ba Y, Xing Q, Du JL. Diabetes mellitus and the risk of fractures at specific sites: a 
meta-analysis. BMJ Open. 2019;9(1):e024067. 
90. Shah VN, Wu M, Foster N, Dhaliwal R, Al Mukaddam M. Severe hypoglycemia is associated 
with high risk for falls in adults with type 1 diabetes. Arch Osteoporos. 2018;13(1):66. 
91. Shah VN, Joshee P, Sippl R, Pyle L, Vigers T, Carpenter RD, et al. Type 1 diabetes onset at 
young age is associated with compromised bone quality. Bone. 2019;123:260-4. 
92. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip 
fractures in the United States. Jama. 2009;302(14):1573-9. 
93. Noordzij M, van Diepen M, Caskey FC, Jager KJ. Relative risk versus absolute risk: one 
cannot be interpreted without the other. Nephrol Dial Transplant. 2017;32(suppl_2):ii13-ii8. 
94. Noordzij M, Leffondre K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need 
competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant. 
2013;28(11):2670-7. 
95. Tang X, Liu G, Kang J, Hou Y, Jiang F, Yuan W, et al. Obesity and risk of hip fracture in 
adults: a meta-analysis of prospective cohort studies. PloS one. 2013;8(4):e55077-e. 
96. Evans AL, Paggiosi MA, Eastell R, Walsh JS. Bone density, microstructure and strength in 
obese and normal weight men and women in younger and older adulthood. J Bone Miner Res. 
2015;30(5):920-8. 
97. Bhupathiraju SN, Hu FB. Epidemiology of Obesity and Diabetes and Their Cardiovascular 
Complications. Circ Res. 2016;118(11):1723-35. 
98. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for 
examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled 
trials. Bmj. 2011;343:d4002. 
99. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, et al. FRAX 
underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301-8. 
 49 
100. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, et al. 
Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. 
Jama. 2011;305(21):2184-92. 
101. Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycaemic 
events and fall-related fractures in Medicare-covered patients with type 2 diabetes. Diabetes 
Obes Metab. 2012;14(7):634-43. 
102. Jensen MH, Vestergaard P. Hypoglycaemia and type 1 diabetes are associated with an 
increased risk of fractures. Osteoporos Int. 2019;30(8):1663-70. 
103. Anagnostis P, Paschou SA, Gkekas NN, Artzouchaltzi AM, Christou K, Stogiannou D, et al. 
Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a 
systematic review. Endocrine. 2018;60(3):373-83. 
104. Ferrari S, Eastell R, Napoli N, Schwartz A, Hofbauer LC, Chines A, et al. Denosumab in 
postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and 
FREEDOM extension. Bone. 2020;134:115268. 
 
